Compounded Semaglutide Bioequivalence: What 503A Pharmacies Actually Have to Test

Compounded semaglutide is, by some estimates, the most prescribed weight-loss medication in the United States that doesn't legally exist as an FDA-approved drug. Tens of thousands of vials a week ship from compounding pharmacies through telehealth intermediaries, sold at a fraction of the cash price of brand-name Wegovy or Ozempic. The marketing on both sides of the debate is loud and confident: telehealth companies imply the molecule is identical to what Novo Nordisk sells, and Novo Nordisk implies compounded versions are unregulated and dangerous. Neither framing survives a careful look at the regulatory rules.

The honest version of the story is that compounded semaglutide sits in a deliberate carveout in federal drug law — one that has nothing to do with bioequivalence trials, never required them in the first place, and was originally written for a totally different purpose. Whether the compounded vial in a patient's refrigerator is “the same molecule” as Wegovy depends on which pharmacy made it, what salt form they sourced, what tests they ran, and whether they meet a standard most patients have never heard of. This is a walk through the actual rules and what they do and don't guarantee.^[1]

Why compounded semaglutide exists at all

The legal foundation for compounding sits in two sections of the Federal Food, Drug, and Cosmetic Act: section 503A, which covers traditional compounding pharmacies that fill patient-specific prescriptions, and section 503B, which created a newer category of “outsourcing facilities” that can ship larger volumes without a name on every vial. Both carveouts let pharmacies prepare drug products that are not FDA-approved, under conditions that exempt them from the new-drug application process that brand-name manufacturers go through.^[2]

The catch is that, ordinarily, you can't compound a copy of a commercially available FDA-approved drug. That rule exists to prevent compounders from simply undercutting brand manufacturers on patented medications. The exception — and the entire reason compounded semaglutide became a category at all — is section 506E of the FDCA, which directs the FDA to maintain a public drug shortage list. When a drug is on that list, the prohibition against compounding copies of it is temporarily lifted. The intent was clearly to let hospitals and infusion centers keep critical drugs flowing during supply disruptions, not to stand up a parallel retail market for weight-loss injections, but the statute doesn't distinguish.^[3]

Semaglutide was added to the FDA drug shortage list in 2022 as Novo Nordisk struggled to keep up with Ozempic and Wegovy demand. That listing, which lasted into early 2025, was the legal hook that made it possible for compounding pharmacies and the telehealth companies that contract with them to produce and sell semaglutide at scale. When the FDA officially declared the shortage resolved in early 2025, the compounding carveout under 506E technically closed for semaglutide, though the FDA gave pharmacies a wind-down window and several compounders are now relying on alternative legal arguments (custom dosing, allergy exemptions, peptide formulations) to continue dispensing.^[2]

503A vs 503B: a meaningful distinction

Not all “compounding pharmacies” are the same. Section 503A pharmacies are state-licensed, regulated primarily by state boards of pharmacy, and required to fill prescriptions one patient at a time. They can't legally ship across state lines in bulk without a patient-specific prescription, and the FDA does not routinely inspect them. Their quality bar is set by the United States Pharmacopeia (USP) chapters — principally USP <797> for sterile compounding — plus whatever their state board enforces.^[4]

Section 503B outsourcing facilities are a different animal. They register directly with the FDA, submit to FDA inspections, and are required to comply with current Good Manufacturing Practice (cGMP) regulations — the same framework that governs brand-name pharmaceutical manufacturing. They can ship in bulk to clinics and hospitals without patient-specific prescriptions. The cGMP requirement is the meaningful difference: it imposes documented batch records, validated processes, environmental monitoring, stability testing, and out-of-specification investigations that 503A pharmacies are not required to do at the same level.^[2]

For a patient receiving compounded semaglutide through a telehealth provider, the question of whether the source pharmacy is 503A or 503B is one of the most consequential pieces of information about the product, and one of the hardest to extract from the marketing copy. Most large telehealth GLP-1 brands source from 503A pharmacies, because the lower regulatory overhead translates to lower per-vial cost. A smaller number source from 503B outsourcing facilities; those tend to be the ones whose pricing sits at the higher end of the compounded market.

The salt-form controversy

Brand-name semaglutide — Ozempic, Wegovy, and the oral Rybelsus — is formulated as a specific molecular entity that the FDA approved on the basis of Novo Nordisk's pivotal trials. The active ingredient is the semaglutide peptide in its base form. A significant fraction of compounded semaglutide on the U.S. market is, by contrast, formulated as semaglutide sodium or semaglutide acetate — salt forms of the same peptide that have never been used in any FDA approval and never appeared in a pivotal trial.^[6]

The FDA has flagged this directly. In a series of communications beginning in late 2023, the agency stated that semaglutide salts are “different active ingredients” than the semaglutide base used in Ozempic and Wegovy, and that compounders using salt forms are not, in the agency's view, producing a drug whose safety and effectiveness can be inferred from the brand-name clinical record. Compounders argue that the peptide is the same molecule once it dissolves in solution, and that the counter-ion (sodium or acetate) is biologically inert. Both positions have a kernel of truth. Pharmacologically, salt forms of the same active moiety usually do behave similarly in vivo — that's why the FDA allows generic manufacturers to use different salts of an active ingredient under certain conditions. But “usually” isn't a clinical trial, and there is no published head-to-head pharmacokinetic study comparing semaglutide base to semaglutide sodium or semaglutide acetate in humans at therapeutic weight-loss doses.^[6]

The honest assessment is that most of the rapid weight loss being reported in the wild on compounded semaglutide is clinically consistent with what you would expect from a real GLP-1 receptor agonist hitting its target, which suggests the salt-form question is probably not a complete deal-breaker in practice. But absence of pharmacokinetic data is not evidence of equivalence, and patients deserve to know which category their product falls into.

What “bioequivalence” actually means

The word “bioequivalence” gets thrown around a lot in compounded GLP-1 marketing, almost always incorrectly. The FDA's definition is precise: two drug products are bioequivalent if they have no significant difference in the rate and extent to which the active ingredient becomes available at the site of action when administered at the same molar dose under similar conditions. Operationally, that gets measured as the area under the plasma concentration-time curve (AUC) and the peak plasma concentration (Cmax), with the generic product's 90% confidence interval required to fall within 80–125% of the reference product on both metrics.^[2]

Bioequivalence trials are the regulatory mechanism by which generic drugs get approved as substitutable for brand-name originators. They require dosing healthy volunteers, sampling plasma at intervals, running mass-spectrometry assays, and statistical analysis of the resulting curves. They are not cheap, but they are the cheapest path to a therapeutically substitutable copy of an existing drug.

Compounded products are not generic drugs, do not go through the abbreviated new drug application (ANDA) pathway, and by definition have not undergone bioequivalence testing. This is not a regulatory loophole or an oversight — it is the explicit structure of the compounding carveout. Compounders are not making the claim that their product is therapeutically equivalent to Wegovy in the regulatory sense, and they are not legally allowed to make that claim. The carveout exists precisely so they don't have to. Anyone marketing a compounded GLP-1 as “bioequivalent to Wegovy” is using the word in the colloquial sense (“basically the same”) rather than the regulatory sense, and the distinction matters because no compounded product on the market has the data that would actually support the regulatory claim.^[6]

What 503A pharmacies actually test

If compounders aren't running bioequivalence trials, what are they testing? The required quality controls under USP <797> for sterile preparations are real and meaningful, even if they're narrower than what brand manufacturers do. A reputable 503A pharmacy compounding injectable semaglutide is required, at minimum, to perform or arrange for:

• Sterility testing under USP <71>. Cultures grown from finished product samples to verify the absence of bacterial and fungal contamination. Required before release for any sterile compound with a beyond-use date longer than the immediate dispensing window.
• Endotoxin testing under USP <85>. Bacterial endotoxins (lipopolysaccharide fragments from gram-negative bacteria) can contaminate sterile injections even when the product itself is technically sterile, because dead bacterial debris survives sterilization. Endotoxins cause fever, hypotension, and shock at very low concentrations. Pyrogen testing is one of the most important quality checks in injectable compounding.^[4]
• Potency / assay testing. A high-pressure liquid chromatography (HPLC) or mass spectrometry assay to confirm the actual concentration of semaglutide in the finished vial matches the labeled concentration. USP allows a typical tolerance band of roughly 90–110% of label claim, though the standard varies by drug class.
• Identity verification. Confirmation that the active ingredient actually is semaglutide, typically via mass spectrometry of the bulk powder before compounding, and ideally again on finished product.
• Beyond-use dating studies. Stability data to support the expiration date printed on each vial, accounting for the specific formulation, container, and storage conditions used.

What 503A pharmacies do not have to test is also worth being explicit about: there is no requirement for bioavailability studies, no requirement for clinical efficacy data, no requirement for head-to-head comparison against Wegovy, no requirement for long-term stability beyond the labeled beyond-use date, and no required post-marketing adverse event reporting comparable to what brand manufacturers submit through FAERS. The quality signal from a 503A pharmacy is a snapshot of identity, sterility, and potency at the moment of dispensing — nothing about clinical performance.

What 503B outsourcing facilities do differently

Outsourcing facilities operating under section 503B layer cGMP requirements on top of the USP chapters. In practice that means a meaningfully thicker quality system: validated equipment cleaning protocols, written master batch records signed off by quality assurance, environmental monitoring of compounding suites, formal supplier qualification of active pharmaceutical ingredient (API) sources, stability programs that follow ICH guidelines, and FDA inspections that look like the inspections done at brand-name manufacturing sites.^[2]

The result is not the same thing as an FDA-approved drug — there is still no NDA, no clinical trial data, no bioequivalence package — but the manufacturing process looks structurally similar to how brand drugs are made. For patients who care about quality assurance and are willing to pay a premium for it, sourcing from a 503B outsourcing facility is the closest thing to a brand-equivalent compounded product currently available. The trade-off is cost: 503B-sourced compounded semaglutide typically lands at 50–100% above the cheapest 503A-sourced offerings.

The PCAB accreditation distinction

PCAB (the Pharmacy Compounding Accreditation Board, now part of ACHC) is a third-party accrediting body that audits compounding pharmacies against a published standard substantially more rigorous than baseline state-board licensure. PCAB accreditation is voluntary — pharmacies choose to apply, pay for the audit, and submit to ongoing inspections. The accreditation verifies that a pharmacy has documented standard operating procedures, a functional quality assurance program, trained personnel, and a track record of compliance with USP chapters and applicable state and federal regulations.^[5]

It is not the same as an FDA inspection, and it does not substitute for cGMP, but it is one of the few external signals available to a patient or prescriber that a 503A pharmacy operates above the regulatory floor. PCAB accreditation status is publicly searchable through the ACHC directory; a pharmacy that claims accreditation but does not appear in the directory is a red flag, and a pharmacy that has never sought accreditation is not necessarily bad but is also not externally audited beyond what its state board requires. For a high-volume product like compounded semaglutide, where quality variability has real clinical stakes, PCAB accreditation is the single easiest filter a patient can apply.

Real-world quality concerns

The FDA's Adverse Event Reporting System has logged a meaningful number of reports tied to compounded GLP-1s since the category became mainstream. The agency's public statements on the topic identify a handful of recurring issues: overdose events traced to confusion between micrograms and milligrams in compounded formulations (semaglutide is dosed in fractions of a milligram, and a tenfold mislabeling error is functionally a tenfold overdose); adverse events tied to non-base salt forms whose pharmacokinetics are not fully characterized; contamination events in pharmacies that cut corners on USP <797> aseptic technique; and potency variability in which finished vials assayed substantially below or above label claim.^[8]

The right way to read these reports is neither “compounded GLP-1s are reckless” nor “everything is fine.” The base rate of catastrophic adverse events from any reputable PCAB-accredited compounder is quite low, and the bulk of the reported overdoses trace to a handful of pharmacies with documented quality system failures and to telehealth intermediaries that pushed do-it-yourself dosing instructions onto patients without adequate guardrails. The variance across compounders is the actual story — the ceiling is reasonable, the floor is not, and which one a patient gets depends on the specific pharmacy their telehealth provider contracts with.^[7]

Pharmacy professional organizations including ASHP and ISMP have published guidance specifically flagging compounded GLP-1s as a high-alert medication category, primarily because of the dosing-error risk and the absence of manufacturer-grade labeling on most compounded vials. The guidance recommends that prescribers and pharmacies treat compounded semaglutide with the same caution applied to insulin and chemotherapy — double-check dose calculations, verify patient understanding of the injection volume, and avoid handing off dose-conversion math to patients without supervision.^[9]

What a careful patient should ask

For a patient who has decided that compounded semaglutide is the right call — whether for cost, access, or flexibility reasons — the questions worth getting clear answers to before the first injection are concrete and answerable. None of them require a pharmacology degree, and none of them are unreasonable for a telehealth provider to address in writing.

1. Which pharmacy fills the prescription, and is it a 503A or a 503B facility? The answer should be a specific pharmacy name. “Our network of partner pharmacies” is not an answer. If the provider can't or won't name the source, that is a meaningful signal.
2. Is the pharmacy PCAB accredited? Verify the answer independently in the ACHC directory rather than taking the marketing copy at face value.
3. What salt form of semaglutide is used? Semaglutide base is the form used in Wegovy and Ozempic. Semaglutide sodium and semaglutide acetate are the alternative forms the FDA has flagged. There is no shame in either answer, but a provider unwilling to state which form they sell is a problem.
4. Does the pharmacy provide a certificate of analysis on each batch? A reputable compounder will produce documentation of identity, potency, and sterility testing on the specific lot the patient receives. Asking for it once is reasonable; being refused is informative.
5. Who calculates the dose, and how? The answer should not be “you do, based on the instructions on the box.” A safer setup involves a clinician confirming the injection volume in writing and the pharmacy labeling each vial with the milligrams-per-milliliter concentration in plain language.

The compounded semaglutide market is going to keep existing for the foreseeable future, regardless of where the FDA drug shortage list lands and regardless of which legal theories survive Novo Nordisk's ongoing lawsuits against the largest telehealth players. The category isn't going away because the underlying access and cost problems with brand-name GLP-1s haven't gone away. The right response from a consumer-protection standpoint isn't to pretend the product doesn't exist or to assume it's uniformly dangerous — it's to ask the small number of questions that separate the responsible end of the market from the careless end. The information is available; the gap is between patients knowing they have the right to ask and providers being willing to answer plainly.